Login / Signup

Interferon-free hepatitis C treatment increases a surrogate of atherosclerotic cardiovascular disease risk in Black veterans living with HIV.

Poonam MathurHabib O RamadhaniRoman KaplanKristen A StaffordAmanda TheppoteEleanor Wilson
Published in: AIDS (London, England) (2024)
Veterans living with HIV (VLWH) and hepatitis C virus (HCV) co-infection have an exacerbated risk of cardiovascular disease (CVD). It is unknown if HCV cure reduces CVD risk in this population. We evaluated changes in low-density lipoprotein (LDL), as a surrogate of CVD risk, 18 months after HCV cure in VLWH. We found significant increases in LDL in VLWH with advanced fibrosis, potentially increasing CVD risk. Lower LDL thresholds to initiate lipid-lowering therapies in VLWH after HCV cure may be warranted.
Keyphrases
  • hepatitis c virus
  • cardiovascular disease
  • low density lipoprotein
  • human immunodeficiency virus
  • type diabetes
  • dendritic cells
  • combination therapy